The future of neuro-oncology.
Treatment options for patients with malignant primary and metastatic lesions to the brain are limited and offer little therapeutic benefit. Despite the use of conventional therapy survival of patients is measured in weeks and months. The use of gene therapy with ganciclovir administration and immunotherapy using targeted protein toxins are two experimental approaches to improving this poor prognosis through regional therapy.